Envoy Medical, Inc. terminated its At The Market Offering Agreement dated January 17, 2025, on June 24, 2026. Envoy Medical, Inc. is a medical device company that develops and manufactures specialized respiratory-related medical devices.

Envoy Medical, Inc. announced on June 19, 2026, that its Compensation Committee approved an updated base salary of $420,000 and a $105,000 target cash bonus for CEO Brent Lucas. The Committee also granted 1,000,000 stock options with an exercise price of $0.634 per share and 1,000,000 restricted stock units (RSUs) that vest upon FDA approval of the Acclaim cochlear implant between 06/19/2026 and 06/18/2030. Envoy Medical, Inc. operates in the medical device industry and develops cochlear implant technology.